Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04167540
PHASE1

GDNF Gene Therapy for Parkinson's Disease

Sponsor: Brain Neurotherapy Bio, Inc.

View on ClinicalTrials.gov

Summary

The objective of this Phase 1b investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a recent or a long-standing diagnosis of PD.

Official title: Open-Label Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2- GDNF) in Parkinson's Disease

Key Details

Gender

All

Age Range

35 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

11

Start Date

2020-04-01

Completion Date

2027-06

Last Updated

2025-09-19

Healthy Volunteers

No

Interventions

BIOLOGICAL

AAV2-GDNF

Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose

Locations (3)

University of California Irvine

Irvine, California, United States

University of California San Francisco

San Francisco, California, United States

The Ohio State University Medical Center

Columbus, Ohio, United States